Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MIDRIX-CTRL DCs
- Development stage
- Unknown
- Lead developer
- Ghent University Hospital
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intradermal
01
Overview
MIDRIX-CTRL DCs are autologous dendritic cells used as a control intervention in the MIDRIXNEO-LUNG Phase I clinical trial (NCT04078269) conducted by University Hospital, Ghent. These cells are derived from the patient but, unlike the therapeutic MIDRIXNEO-LUNG vaccine, they are not loaded with tumor-specific neoantigens. They are administered via intradermal injection to perform delayed-type hypersensitivity (DTH) skin testing. This procedure serves as a baseline to assess non-antigen-specific immune reactivity, allowing researchers to distinguish between general background immune activation and the specific cytotoxic T-cell responses induced by the neoantigen-targeted vaccine in patients with resected non-small cell lung cancer (NSCLC).
- Other names
- Control DTHControl DTH-University Hospital, Ghent-non-small cell lung cancer
02
Targets
pMHC-II (Peptide-major histocompatibility complex class II complex)
Beyond the preview
Go deeper on MIDRIX-CTRL DCs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MIDRIX-CTRL DCs.